RG
VRTX icon

Redmile Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Redmile Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-189,008
Closed -$28.7M – 78
2017
Q3 		$28.7M Buy
189,008
+44,600
+31% +$6.71M 1.42% 27
2017
Q2 		$18.6M Buy
+144,408
New +$17.4M 1.13% 34
2013
Q4 		– Sell
-108,262
Closed -$8.21M – 65
2013
Q3 		$8.21M Buy
+108,262
New +$8.61M 1.24% 32

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Redmile Group's VRTX Position: Q4 2017 in Review

Redmile Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 189,008 shares — an estimated $28.7M sold.

Redmile Group first reported a position in VRTX in Q3 2013 and held it in 3 quarters. The position peaked at $28.7M in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Redmile Group reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Redmile Group sold 189,008 Vertex Pharmaceuticals shares in Q4 2017, an estimated $28.7M.
  • Redmile Group first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Redmile Group's Vertex Pharmaceuticals position peaked at $28.7M in Q3 2017.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.